Last updated: 2026-08-07
What's Actually Different Under the "Stem Cell Injection" Label
When researching stem cell injections, look at the source material and the specific component being used — not just the name. Centrifuging your own blood yields platelet-rich components such as PRP or PRF; processing fat or bone marrow can produce cell-based preparations depending on how they're handled. Exosomes — small particles secreted by cells — are a separate category from living cells.
Autologous blood regenerative therapy draws your blood, spins it in a centrifuge, and separates out the needed layer. What you get from that process is not always stem cells. Platelet-rich plasma (PRP), platelet-rich fibrin (PRF, which combines platelets with a fibrin mesh), and specific cell-fraction preparations all differ in name and composition, so it's worth knowing exactly what is being injected.
Platelets release growth factors — PDGF, TGF-β, and VEGF among them. These growth factors carry signals between cells at the injury site, drive collagen synthesis, and support new blood vessel formation, while fibrin forms the mesh-like scaffold that holds these materials in place. Therapies that deliver cells directly and therapies that harness the repair signals from platelets are therefore meaningfully different treatments.
Exosomes are a third category. They are small delivery particles released by cells, carrying proteins and fragments of genetic information, and they are not living cells. Culturing cells to expand their numbers is also a different process from centrifuging blood to separate its components. Understanding the source material, how it's processed, and what ultimately enters the body is what reveals the true nature of any given treatment.
Why the Treatment Is Organized Into 8 Steps — From Diagnosis to Follow-Up
The Thewells stem cell therapy program is structured as an 8-step course — meaning it begins with diagnosis and closes with follow-up care, not just the injection itself.
This course is typically considered by people who have recurring knee pain and are weighing whether to continue with injections, people using hair loss medication who also want to address scalp health, or people receiving treatment for neck muscle symptoms that turn the head involuntarily to one side. Because each starting point is different, the first step is always diagnosis, not a procedure.
The process begins with a personalized assessment covering general health and any related conditions. Your blood is then spun in a blood centrifuge to isolate the needed components, which are activated under quality-control procedures before being precisely applied to the identified area. Subsequent steps evaluate the immune environment and help manage inflammatory burden, while joint, skin, and fatigue or pain concerns are reviewed at each stage. The final three steps cover safety monitoring, scheduled progress checks, and refining the plan based on domestic and international clinical research. The step-by-step structure and equipment used are detailed on the Jamsil Main Branch Stem Cell Treatment Program page.
Diagnosis needs to be specific. For knee pain, the assessment distinguishes whether the source is inside the joint itself or originates from the patellar tendon or surrounding ligaments. When swelling and warmth are present, inflammation and joint fluid status are evaluated first before deciding on the target area and timing. For intra-articular problems, imaging and physical examination findings are combined to pinpoint the injection site. When a tendon or ligament is the source, ultrasound is used to locate the damaged area and define the treatment zone.
For scalp applications, the initial assessment notes the extent of thinning, along with any redness, weeping, or open scratches. Any active issues are addressed and the skin is allowed to settle before the treatment component and depth are determined. Once the skin has healed, the planned treatment proceeds.
After the procedure, swelling, warmth, and pain changes are reassessed alongside joint mobility or skin condition. If general fatigue is also present, sleep quality, nutritional status, related conditions, and current medications are reviewed, and referrals are made as needed.
That is why post-treatment care is built into the 8 steps. Following knee treatment, walking distance, stair discomfort, and how long it takes before swelling returns are tracked to guide rehabilitation intensity. For the scalp, the pace at which redness and irritation settle determines when the next care session is scheduled. Recording both the rationale for targeting a particular area and the response afterward makes it easier to decide whether to continue the same approach or revise the plan.
This Treatment Is Not Limited to Joints
The same base material is applied differently depending on whether the target is a joint, the scalp, or the neuromuscular system. Both the diagnostic approach and the actual substance used vary by area, so it's helpful to consider each separately.
The scalp is addressed through the HeadReset Fit program. A Dermashine multi-injector delivers the substance evenly across the scalp, and the specific option — placenta extract, BENEV growth factors, stem cell peptides, or a combination of stem cells and exosomes — is selected based on the individual assessment. Before starting, the scalp is checked for active inflammation or open wounds; any issues are resolved and the skin is settled before moving to the injection phase.
Neuromuscular concerns are handled through the cervical dystonia and dystonia program. Cervical dystonia causes the neck to turn or tilt to one side involuntarily; dystonia is a condition in which muscles contract without the person's control. The second of the nine steps in this course is stem cell and neural regeneration therapy. Neck range of motion, abnormal muscle contractions, pain, and neurological function are all evaluated before a plan is made.
Knee osteoarthritis is an area with a relatively larger body of cell therapy research. A 2023 domestic randomized clinical trial evaluated the clinical efficacy and safety of intra-articular injection of autologous adipose-derived mesenchymal stem cells in patients with knee osteoarthritis (Kim et al., 2023). A 2019 overseas randomized controlled trial examined the same condition and the same cell type (Freitag et al., 2019).
The source of the evidence matters for interpreting it correctly. Both studies used cells derived from the patient's own fat tissue, so their findings cannot be directly extended to components separated from blood. The study populations were also limited to knee osteoarthritis — these results should not be read as applying to other joints, the scalp, or neuromuscular conditions.
Research titles alone can obscure the difference between cells and exosomes. A 2025 paper reviewed preclinical studies and limited early clinical data on intra-articular injection of exosomes derived from human umbilical cord mesenchymal stem cells for knee osteoarthritis (Wang et al., 2025). The material used in that research was the exosomes those cells secreted — not the umbilical cord cells themselves. Autologous blood components, autologous adipose-derived cells, and umbilical cord–derived exosomes each sit within a different body of evidence, and keeping them separate is what allows you to understand what each study actually addresses.
Why the Same "Stem Cell Injection" Differs So Much Between Clinics
At Thewells, the components used are derived from the patient's own blood, separated by centrifuge, and activated under quality-control procedures. Cells from donor tissue are not used.
Cost is not determined by the treatment name alone. It varies depending on whether blood separation is performed, whether cell culturing is involved, how many areas are treated, and how many sessions are planned. Whether post-procedure testing, rehabilitation, and follow-up checks are included also affects the total. Before comparing prices, confirming what substance is actually being applied and what follow-up is covered will prevent two different treatments from being mistaken for the same thing under a shared name.
Knee osteoarthritis is not assessed from a single MRI or X-ray. The evaluation includes the type and duration of previous treatments, the difference between pain at rest and pain during walking, how far a person can walk on flat ground without stopping, and whether a handrail is needed on stairs. A systematic review of clinical practice recommendations for hip and knee osteoarthritis management also covered comprehensive patient evaluation approaches that incorporate symptoms and physical function (Gibbs et al., 2023).
Assessment findings feed directly into the treatment plan. When intra-articular inflammation and swelling are prominent, those are addressed first. If pain improves but walking distance and stair use do not change, muscle strength and mobility are reassessed and the rehabilitation content is adjusted.
How Safety Is Managed — and When to Seek Care First
Safety management begins at the moment blood is drawn. Blood is separated and the needed components are prepared according to established quality-control procedures, applied to the assessed area by the planned method, and then monitored with scheduled checks for adverse reactions and progress.
Even when the material comes from your own body, the contamination-prevention procedures during collection and processing, and the route of application, all warrant explanation. You should also be informed of the risk of bleeding or infection at the treatment site and what the response protocol would be. When a clinic uses cells or secreted particles from donor tissue, it's reasonable to ask about the source and the manufacturing and testing process.
Stem cell interventions that lack adequate supporting evidence have been identified as a global public health concern, not just an individual choice (Master et al., 2021). A "stem cell" label or an autologous origin claim alone does not indicate the level of evidence or safety profile. Checking which conditions and which cell or component sources a study actually examined — and whether the treatment you're considering falls within that scope — is a practical way to calibrate your expectations.
Persistent redness, warmth, or discharge at the treatment site should prompt evaluation for infection. If chills or fever develop alongside those signs, getting a blood test and local assessment at a clinic rather than waiting is the better course. If infection is confirmed, identifying the causative organism and the extent of inflammation takes priority over the regenerative treatment schedule; the timeline is reset after appropriate treatment has been completed.
Rapid worsening of unexplained pain or sudden weakness in the arms or legs also warrants prompt evaluation. Numbness or difficulty walking should lead to assessment for urgent causes — nerve injury, infection, or fracture — before any regenerative treatment is discussed. Safety management doesn't end on the day of the procedure; it runs from the point at which source materials are verified through to the response to any post-treatment symptoms.
This content is provided for general medical information purposes only and may not apply to your individual circumstances. Consulting a specialist for accurate diagnosis and treatment is important.
References
- Kim, Lee, Lee (2023). Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis. The American Journal of Sports Medicine. PMID: 37345256
- Freitag, Bates, Wickham (2019). Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial. Regenerative Medicine. PMID: 30762487
- Wang, Kong, Du (2025). Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis: from preclinical to clinical. Journal of Translational Medicine. PMID: 40500748
- Gibbs, Gray, Wallis (2023). Recommendations for the management of hip and knee osteoarthritis: A systematic review. Osteoarthritis and Cartilage. PMID: 37394226
- Master, Matthews, Abou-El-Enein (2021). Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports. PMID: 34107243
Frequently Asked Questions
Q. What is the difference between autologous blood stem cell injections and PRP or PRF?
PRP and PRF separate the platelet-rich layer from your own blood, and they are generally distinct from living stem cell preparations. Rather than focusing on the name, check whether the final substance being applied is a platelet concentrate, a fibrin-containing component, or an actual cell preparation.
Q. How do autologous blood treatments differ from fat-derived, bone marrow–derived, or allogeneic (donor) stem cell treatments?
Autologous blood therapy uses components separated from the patient's own blood. Fat- and bone marrow–derived treatments use cells or mixed fractions obtained from those tissues. Allogeneic treatments use material from a donor, so the source and the manufacturing and testing process should be verified. Each approach differs in collection burden and in what is ultimately applied.
Q. What is assessed before treatment in the joint, scalp, and neural regeneration programs?
For joints, the anatomical location of pain and the inflammatory status are confirmed first. For the scalp, the pattern of hair loss and the presence of skin inflammation or open wounds are assessed before proceeding. Neuromuscular symptoms require an accurate diagnosis and a review of prior treatment history. The substance used and the target area may vary based on the findings from each area's evaluation.
Q. After the procedure, when should redness, warmth, or pain prompt a clinic visit?
Mild redness or discomfort can appear temporarily after a procedure. If these worsen over time, or are accompanied by swelling, discharge, or fever, medical evaluation is needed. Sudden systemic symptoms — difficulty breathing, widespread hives, or changes in consciousness — require immediate emergency assessment.
Q. What is the sequence of stem cell treatment at Thewells?
The process begins with a personalized assessment of general health and related conditions. Your blood is then separated by centrifuge, the components are activated under quality-control procedures, and they are applied to the identified area. Follow-up steps evaluate the immune environment and inflammatory load, and joint, skin, fatigue, and pain concerns are reviewed throughout. Scheduled progress monitoring is included within the 8-step structure.